Yüksel Ürün/X
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“Big win for bladder cancer care!
FDA approves neoadjuvant and adjuvant durvalumab (NIAGARA trial) in MIBC!
Chemo and immunotherapy before surgery. Immunotherapy after.
PFS and OS both improved.
Proud to be one of investigator of this milestone!”
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51